Giant Cell Tumor of Bone
Conditions
Interventions
Trial group:The patient received intravenous ICG before conventional curettage of giant cell tumor of bone. After routine intraoperative curettage, the procedure of fluorescence imaging of tumor cavit
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-65 years, with closed epiphyseal plates. 2. Confirmed diagnosis of primary giant cell tumor of bone (GCTB) via preoperative biopsy. 3. Tumor suitable for extensive curettage, with Campanacci grade II or III. 4. Able to understand the study and voluntarily sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Known severe allergy to ICG or iodine. 2. Severe liver dysfunction. 3. Female subjects who are pregnant, lactating, or planning to become pregnant during the study period. 4. Recurrent cases or those previously treated with Denosumab. 5. Cases with severe pathological fractures unsuitable for curettage.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The accuracy of ICG fluorescence imaging in displaying GCTB lesions, including sensitivity, specificity, positive predictive value and negative predictive value; | — |
Secondary
| Measure | Time frame |
|---|---|
| Spatial overlap of ICG fluorescence boundary and pathological boundary;Correlation between Microvessel Density (MVD) and Tumor-to-Background Ratio(TBR);Correlation between TBR and Campanacci classification;Incidence of Adverse Events; | — |
Countries
China
Contacts
Public ContactYang Qingcheng
Shanghai Sixth People's Hospital
Outcome results
None listed